Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Patient-reported data reveal substantial gaps between clinical perception and lived experience across sleep, mental health, and daily functioning EXTON, PA, January 8, 2026 – More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep,
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European approval last month. Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before the end of the year. As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential
High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie’s Rinvoq continue to generate strong future interest EXTON, PA, December 17, 2025 — New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as dermatologists reassess
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON, PA, December 11, 2025 — Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights’ latest RealTime Dynamix™: Lupus Nephritis
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness. Exton, PA., December 9, 2025 – Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National
Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA., December 2, 2025 – “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and you’ll get five different answers. It’s
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. EXTON, Pa., November 19, 2025 – Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the commercial
New chart-audit data reveal faster referrals, more patients initiating advanced therapy before hematology consultation, and heightened disease awareness among community physicians. Exton, PA., November 19, 2025 — New data from Spherix Global Insights reveal that the U.S. market for paroxysmal nocturnal hemoglobinuria (PNH) is entering a new phase of dynamism, characterized by shifting
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab. EXTON, PA, November 13, 2025 – The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape,
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in 2026 EXTON, PA, November 12, 2025 — New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED),
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to Spherix Global Insights EXTON, PA, November 6, 2025 – According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix Global Insights. Exton, PA., November 03, 2025 – Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV) leading prescribing. Exton, PA., October 29, 2025 – Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a comprehensive view of real-world
Exton, PA., October 28, 2025 – The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, according to Spherix Global Insights’ recently published Market Dynamix™: Membranous Nephropathy (US) 2025 service. Nephrologists describe MN as one
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
